Ciprofloxacin injections for treating skin leishmaniasis
Effectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative Trial
This study is testing if ciprofloxacin injections can effectively treat skin leishmaniasis compared to the standard treatment with sodium stibogluconate.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Al-Mustafa University College Academic / other |
| Locations | 1 site (Baghdad) |
| Trial ID | NCT06798402 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of intralesional ciprofloxacin 0.2% solution as a treatment for cutaneous leishmaniasis, comparing it to the standard treatment of intralesional sodium stibogluconate (SSG) 10%. Patients are randomly assigned to receive either ciprofloxacin or SSG injections, with each lesion treated as a separate case. The lesions will be monitored for 90 days or until they are cured to assess the treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients with one to six lesions of cutaneous leishmaniasis who have not received recent anti-leishmaniasis treatment.
Not a fit: Patients who have received anti-leishmaniasis treatment in the past month or are on prolonged corticosteroid therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a more effective and potentially safer option for patients suffering from cutaneous leishmaniasis.
How similar studies have performed: While this approach is novel in the context of cutaneous leishmaniasis, similar studies using alternative treatments have shown varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis Exclusion Criteria: * Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study * patients on prolonged corticosteroid therapy.
Where this trial is running
Baghdad
- Mustansiriyah University — Baghdad, Iraq (Recruiting)
Study contacts
- Study coordinator: Hayder Adnan Fawzi, PhD
- Email: haider-pharm@almustafauniversity.edu.iq
- Phone: 009647800106177
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.